Analyst Ratings for BioXcel Therapeutics
Portfolio Pulse from Benzinga Insights
BioXcel Therapeutics (NASDAQ:BTAI) has received 7 bullish and 1 indifferent analyst ratings in the last quarter. The company has an average 12-month price target of $51.12, which has increased by 12.35% over the past month.
July 17, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. The predominantly bullish ratings for BioXcel Therapeutics indicate a positive outlook for the company, which could lead to increased demand for the stock and a potential rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100